IVIM & OLINK in Sarcoma

Sponsor
University Health Network, Toronto
Study ID
NCT05950594
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Soft Tissue Sarcoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • Radiotherapy — RADIATION
    Standard of care pre-operative radiotherapy
  • Surgery — OTHER
    Standard of care definitive surgery

Study Details

The hypoxia \> metastasis axis suggests that a DWI-based biomarker of hypoxia incorporating IVIM may be able to predict metastasis in STS patients, ultimately enabling stratification for personalized treatments at the time of diagnostic (MR) imaging, without adding an excessive burden to the patient or clinical workflow (typical DWI/IVIM sequences can be acquired acquired in approximately 5 minutes).

Key Dates

First listed
Jul 18, 2023
Start date
Mar 5, 2024
Status verified
Mar 2026
Primary completion
Nov 30, 2027
Completion
Nov 30, 2027

Study Design

Enrollment
145 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Primary Outcome Measure

Identify image-derived, plasma-derived biomarkers of hypoxia [ Time Frame: 3 years ]

Central Contacts

Related Studies